Comparison of amantadine, placebo, and levodopa in Parkinson's disease
- PMID: 4858417
- DOI: 10.1212/wnl.24.8.715
Comparison of amantadine, placebo, and levodopa in Parkinson's disease
Similar articles
-
Amantadine hydrochloride in treatment of Parkinsonism.Dis Nerv Syst. 1973 Jun-Jul;34(5):253-8. Dis Nerv Syst. 1973. PMID: 4782280 No abstract available.
-
Interactions of L-dopa and amantadine in patients with Parkinsonism.J Neurol Neurosurg Psychiatry. 1973 Jun;36(3):354-61. doi: 10.1136/jnnp.36.3.354. J Neurol Neurosurg Psychiatry. 1973. PMID: 4714097 Free PMC article.
-
Long-term therapy of Parkinson's disease with amantadine, alone and combined with levodopa.Can Med Assoc J. 1973 Oct 6;109(7):588-93. Can Med Assoc J. 1973. PMID: 4582563 Free PMC article. Clinical Trial.
-
Parkinsonism, levodopa, and anesthesia.Anesthesiology. 1972 Sep;37(3):344-51. doi: 10.1097/00000542-197209000-00011. Anesthesiology. 1972. PMID: 4559395 Review. No abstract available.
-
Identifying poor symptom control in Parkinson's disease.Nurs Times. 2006 Mar 21-27;102(12):30-2. Nurs Times. 2006. PMID: 16594560 Review.
Cited by
-
Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect.Br J Clin Pharmacol. 1976 Oct;3(5):883-9. doi: 10.1111/j.1365-2125.1976.tb00642.x. Br J Clin Pharmacol. 1976. PMID: 788761 Free PMC article. Clinical Trial.
-
Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective.Drugs Aging. 1994 Jul;5(1):8-19. doi: 10.2165/00002512-199405010-00002. Drugs Aging. 1994. PMID: 7919641 Review.
-
SARS-CoV-2: At the Crossroad Between Aging and Neurodegeneration.Mov Disord. 2020 May;35(5):716-720. doi: 10.1002/mds.28084. Epub 2020 Apr 24. Mov Disord. 2020. PMID: 32291797 Free PMC article. No abstract available.
-
Amantadine sulphate in treating Parkinson's disease: clinical effects, psychometric tests and serum concentrations.J Neurol. 1989 Mar;236(3):153-6. doi: 10.1007/BF00314331. J Neurol. 1989. PMID: 2709063
-
Economic and health-related quality of life considerations of new therapies in Parkinson's disease.Pharmacoeconomics. 2001;19(7):729-52. doi: 10.2165/00019053-200119070-00003. Pharmacoeconomics. 2001. PMID: 11548910 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources